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 Psoriasis is a chronic inflammatory disease affecting up to 2% of the 
global population. While the pathogenesis of psoriasis is not fully understood, 
yet, increasing body of evidence suggests a genetic predisposition and an 
environmental component. The most common manifestations are 
papulosquamous plaques symmetrically located on extensor surfaces of the 
joints. While most psoriasis patients report that their skin manifestations have a 
negative impact on their quality of life, psoriasis is not just a skin disease. Indeed, 
similar to other systemic inflammatory diseases, inflammation is widespread in 
psoriasis and arthritis is found in up to one quarter of patients that precedes the 
disease in 10% of the patients.1 Importantly, life expectancy is reduced in 
psoriasis by up to 4 years, which has been attributed to a higher incidence of 
cardiovascular diseases.2  
 
 In this issue of the journal, Ahlehoff et al report an association of psoriasis 
with increased risk of atrial fibrillation and ischemic stroke. The authors analyzed 
36’765 patients with mild and 2793 patients with severe psoriasis and compared 
these with over 4 million individuals of a nationwide Danish registry. Indeed, 
several important pieces of information can be retrieved from this study. First, the 
study is a further epidemiological milestone in delineating the associated risk of 
not only severe but also mild psoriasis with vascular disease. Secondly, the study 
demonstrates a considerably elevated risk not only for cardiovascular disease 
per se but for atrial fibrillation and ischemic stroke, in particular. While 
confounding and misclassification might be a concern in any registry based 
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study, the authors provide further evidence that psoriasis is not just a skin, but 
indeed a systemic disease. Notwithstanding patients with psoriasis have a high 
prevalence of cardiovascular risk factors, such as smoking, dyslipidemia, 
hypertension, obesity and insulin-resistance, systemic inflammation beyond the 
skin may provide an explanation for the increased cardiovascular risk observed 
in psoriasis.1 
 Psoriasis shares striking similarities with other systemic inflammatory 
diseases, such as rheumatoid arthritis and atherosclerosis. Intriguingly, the 
typical histologic features of the psoriatic plaque with dermal inflammation and 
leukocyte infiltration are similar to the atherosclerotic plaque (Figure 1).3 In 
atherosclerosis,  psoriasis and rheumatoid arthritis, the activation of the innate 
immune system starts an inflammatory cascade, particularly involving T helper 1, 
T helper 17 and regulatory T-cells and downstream expression of cytokines.4 
Inflammation induced by psoriasis also impacts on insulin resistance both of 
which are important surrogates for early, subclinical atherosclerosis and 
prognostic markers for cardiovascular disease and may alter the function of 
endothelial cells, resulting in a propensity towards endothelial dysfunction and 
early structural changes of the arterial wall. Indeed, several studies demonstrated 
impaired endothelial function and increased intima-media thickness in patients 
with psoriasis.5 
Does atrial fibrillation fit into the story of psoriasis being a systemic 
inflammatory disease? Recent studies established chronic inflammation as a risk 
factor for atrial fibrillation6 which is of particular clinical relevance as inflammation 
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might contribute to the prothrombotic state of atrial fibrillation and its clinical 
sequelae.7 Remarkably, Ahlehoff and colleagues also reported an increased rate 
of venous thromboembolism in their cohort of psoriasis patients.8  
 
Since the paper by Ahlehoff adds to the increasing evidence of increased 
cardiovascular risk in patients with chronic inflammatory diseases, patients with 
psoriasis should be informed by their treating physician that they may have an 
increased chance of cardiovascular disease. This, however, begs two important 
questions with regard to potential therapeutical implications. First, should we be 
more aggressive in treating risk factors in these patients, and secondly should we 
specifically target inflammation? Risk factors should be assessed, and lifestyle 
interventions and pharmaceuticals prescribed as appropriate.9 Since LDL levels 
are elevated and correlate with the severity of psoriasis,10 initiation of statins 
should be considered and goals for LDL cholesterol levels be based on 
cardiovascular risk assessment.. Close monitoring of liver function and 
creatinkinase are mandatory, especially in patients receiving immunosuppressive 
drugs to avoid liver toxicity and rhabdomyolysis. In addition to their well-
documented LDL lowering effects, statins exert additional pleiotropic, anti-
inflammatory effects, that may contribute to the improvement of endothelial 
function demonstrated in patients with atherosclerotic vascular disease as well as 
in patients with rheumatoid arthritis, especially in those with high levels of 
systemic inflammation.11 Intriguingly, cardiovascular treatment aimed at 
preventing and treating atherosclerosis may also be beneficial in reducing 
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psoriasis disease severity, as statins reduced psoriatic cutaneous plaque 
activity.12 While many patients with psoriasis present with low HDL levels,10 there 
is currently no indication for niacin and fibrates in patients with psoriasis, 
especially as both of these drugs are associated with a worrisome higher rate of 
side effects in patients with systemic inflammatory diseases. 
 ln patients with psoriasis and elevated blood pressure, lifestyle changes 
should be implemented and calcium antagonists, thiazide diuretics and 
angiotensin converting enzyme inhibitors (ACE-I) may represent the drugs of first 
choice. ACE-I also exert anti-inflammatory and antioxidative effects and are 
similarly effective as statins in improving endothelial dysfunction in rheumatoid 
arthritis.13 In contrast, beta-blockers should be prescribed with caution since they 
are reported to be associated with the exacerbation of psoriasis. While patients 
with systemic inflammatory disease have not been included in previous 
cardiovascular outcome trials, aggressive management of conventional 
cardiovascular risk factors seems prudent in patients with systemic inflammatory 
disease who show an increased cardiovascular risk similar to that of diabetics. 
The benefit of any specific antiinflammatory therapy, however, remains 
still to be established. In fact, antiinflammatory drugs might be double-edged, 
especially non-steroidal anti-inflammatory drugs (NSAIDs) that are commonly 
used in psoriasis arthritis. Their antiinflammatory and analgesic effects 
notwithstanding, NSAIDs and selective COX-2 inhibitors, increase blood 
pressure and cardiovascular risk.14 Their blood pressure rising effects must not 
be underestimated, notably an effect even observed with paracetamol 
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(acetaminophen),15 as hypertension has well known effects on the incidence of 
atrial fibrillation and stroke. As such, we are facing a dilemma when trying to 
specifically target systemic inflammation. While antiinflammatory drugs hold the 
potential of providing benefit through targeting inflammation, they may exert 
potent off-target effects. This is even more problematic in severely symptomatic 
patients receiving immunosuppressive drugs, since corticosteroids and 
cyclosporine not only increase blood pressure, but also worsen dyslipidemia, all 
further enhancing cardio- and cerebrovascular risk. This true equipoise is further 
documented by observational studies demonstrating beneficial cardiovascular 
effects of low-dose methotrexate.16 This set the stage for cardiovascular outcome 
trials with methothrexate currently under-way and will provide the answer 
whether this anti-inflammatory and immunmodulatory drug will improve survival 
in high-risk cardiovascular patients.  
Novel biologics, such as TNF-alpha inhibitors have been proven highly 
effective in the treatment of psoriasis and other inflammatory diseases. First 
evidence whether potent antiinflammatory treatment would not only alleviate 
symptoms but also impact on cardiovascular surrogates, came from studies 
demonstrating that TNF-alpha suppression improved vascular function in patients 
with rheumatoid arthritis17 and may have beneficial impact on carotid intima 
media thickness in psoriasis.18 Whether TNF-alpha blockade might beneficially 
impact on cardiovascular morbidity and mortality in patients at increased risk 
because of systemic inflammatory disease, however, remains still to be 
determined.  
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Novel targeted biologic agents for the treatment of psoriasis are on the 
horizon, among them several monoclonal anti-Interleukin antibodies like 
briakinumab, ustekinumab and tocilizumab. Due to the sheared immunological 
mechanisms between psoriasis (and other inflammatory diseases) and 
atherosclerosis, they may hold the potential for the treatment of both diseases,3 
but randomized clinical trials addressing efficacy and safety are yet to be 
performed.  
 
Taken together, the present study adds to the increasing body of evidence 
of an association between psoriasis and cardio- and cerebrovascular diseases. 
Although inflammation in these patients may not be limited to skin and joints, but 
indeed be widespread throughout the vascular tree, there is an unmet need for 
further research and outcome trials in this field. As a consequence for clinicians, 
psoriasis patients, particularly those with moderate or severe forms should not 
only be treated for skin lesions and arthritis but also rigorously screened for 
vascular risk factors, especially as these patients are often young and could 
therefore profit most when preventive strategies are implemented early.9 In the 
future, large-scale randomized clinical trial studies are needed to define whether 
patients with systemic inflammatory diseases as psoriasis will benefit form 
aggressive risk factor control and/or anti-inflammatory treatment. 
This would be of particular interest for our specialty, as the benefit of a 
specific antiinflammatory treatment has yet to be established in the systemic 
inflammatory disease we care about the most, atherosclerosis. 
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Figure Legend: 
Figure depicts a much simplified schema for the development of atherosclerotic 
(above) and psoriatic (below) plaques.  
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